Skip to main content
. 2020 Jun 16;8:383. doi: 10.3389/fcell.2020.00383

FIGURE 3.

FIGURE 3

Relationship between ciRNA13761/novel-miR-3880/ELF2 axis and PI3K/AKT/mTOR/S6K1 pathway. (A) Schematic diagram of animal treatment. C57BL/6 mice were injected with novel-miR-3880 or siELF2 in an interval of three days and four days alternatively. Samples were harvested at day 22. (B) Immunohistochemistry of mouse mammary gland for p-PI3K, p-AKT, p-mTOR and p-S6K1 in Normal Saline, novel-miR-3880 and siELF2 groups. (C) Protein phosphorylation level of PI3K, AKT, mTOR and S6K1 in mouse mammary gland. (D,E) Effects of novel-miR-3880 and ELF2 on Bcl2/Bax pathway and protein phosphorylation level of PI3K, AKT, mTOR and S6K1 in MEC. (F) PI3K, AKT, mTOR and S6K1 inhibitors suppressed the phosphorylation of PI3K, AKT, mTOR and S6K1 in MEC. (G–J) The role of novel-miR-3880 and siELF2 in Bcl2/Bax and protein phosphorylation level of PI3K, AKT, mTOR and S6K1 in MEC with PI3K, AKT, mTOR or S6K1 inhibited. (K) Regulation of ciRNA13761 on Bcl2/Bax and PI3K, AKT, mTOR and S6K1 phosphorylation, and the balance effects of novel-miR-3880. (L) Effects of siDOCK1 on Bcl2/Bax and PI3K, AKT, mTOR and S6K1 phosphorylation.